BACKGROUND: Data on the incidence of adverse liver outcomes are limited for cancer patients with chronic (hepatitis B surface antigen [HBsAg]-positive/hepatitis B core antibody [anti-HBc]-positive) or past (HBsAg-negative/anti-HBc-positive) hepatitis B virus (HBV) after chemotherapy. This study was aimed at determining the impact of test timing and anti-HBV therapy on adverse liver outcomes in these patients. METHODS: Patients with solid or hematologic malignancies who received chemotherapy between 2004 and 2011 were retrospectively studied. HBV testing and anti-HBV therapy were defined as early at the initiation of cancer therapy and as late after initiation. Outcomes included hepatitis flares, hepatic impairment, liver failure, and death. Time-to-event analysis was used to determine incidence, and multivariate hazard models were used to determine predictors of outcomes. RESULTS: There were 18,688 study patients (80.4% with solid tumors). The prevalence of chronic HBV was 1.1% (52 of (HR, 3.90; 95% CI,) in comparison with early identification. Among patients with hematologic malignancies and chronic HBV, the risk of death was 7.8 (95% CI, 1.73-35.27) times higher for persons with late initiation of anti-HBV therapy versus early initiation. Patients with late identification of chronic HBV had late or no anti-HBV therapy. Chronic HBV predicted liver failure in patients with solid or hematologic malignancies, whereas male sex and late identification were predictors for patients with solid tumors. CONCLUSIONS: Early identification correlates with early anti-HBV therapy and reduces the risk of liver failure and death in chronic HBV patients receiving chemotherapy. Cancer 2017;123:3367-76.
INTRODUCTION
Hepatitis B virus (HBV) affects nearly 2 billion people worldwide and can lead to serious liver diseases. 1 The balance between liver injury and viral control is regulated by the host immune system, 2 and immunosuppressive therapies that disrupt the immune balance can lead to reactivation of HBV replication and result in hepatitis flares, liver failure, and death. 3 For patients receiving anticancer therapy, HBV testing [4] [5] [6] [7] and anti-HBV medications 8, 9 are recommended to prevent HBV reactivation. However, uptake has been low, 10 particularly for patients with solid tumors, 11 and this may be in part due to the lack of clinical outcome data to support an optimal management strategy. We conducted this retrospective study to determine the impact of early HBV identification versus late identification and the impact of early initiation of anti-HBV therapy versus late/no initiation on the development of adverse liver outcomes among patients with chronic or past HBV infections receiving cancer therapy.
MATERIALS AND METHODS
We assembled a retrospective cohort of patients aged 18 years or older with solid or hematologic malignancies who presented to The University of Texas MD Anderson Cancer Center and received the first outpatient administration of parenteral cancer therapy between 2004 and 2011. We excluded patients with hepatocellular carcinoma because they would be more likely to be screened for HBV and to be treated with anti-HBV therapy if they tested positive. Furthermore, hepatitis flares and liver failure in these patients may be due to underlying liver disease and not to cancer treatment. Demographic and clinical characteristics were obtained from institutional databases. This study was conducted after approval by our institutional review board.
A chronic HBV infection was defined as hepatitis B surface antigen (HBsAg)-positive/hepatitis B core antibody (anti-HBc)-positive or HBsAg-positive/anti-HBcunknown. A past HBV infection was defined as HBsAgnegative/anti-HBc-positive or HBsAg-unknown/antiHBc-positive, regardless of the hepatitis B surface antibody status.
The chemotherapy initiation period was defined as the period from 2 months before the first administration of chemotherapy until the beginning of the second chemotherapy cycle (Fig. 1) . The postchemotherapy initiation period was defined as the period from the beginning of the second chemotherapy cycle to the end of the study period. We defined early HBV identification as 1 or more of the following: HBsAg or anti-HBc tests at MD Anderson during the chemotherapy initiation period, known positive HBsAg or anti-HBc tests, and anti-HBV therapy before first chemotherapy. Late HBV identification was defined as HBsAg and/or anti-HBc tests at MD Anderson after the chemotherapy initiation period. Early initiation refers to anti-HBV medications started before or during the chemotherapy initiation period and before any adverse liver outcome; late initiation refers to medications started after the chemotherapy initiation period before or after an adverse liver outcome.
We identified outcomes between the administration of the second cycle of chemotherapy and 2 years after the last chemotherapy administration at MD Anderson, last follow-up, or death (Fig. 1) . We defined a hepatitis flare as an alanine aminotransferase level 100 U/L that was also 3 times the baseline alanine aminotransferase level in the chemotherapy initiation period. 12 Hepatitis impairment was defined as a hepatitis flare and either a total bilirubin level 2.5 mg/dL or an international normalized ratio 1.5. Liver failure was defined as a hepatitis flare and either ascites or encephalopathy as determined from claims using International Classification of Diseases, Ninth Revision codes. All-cause mortality was determined through our tumor registry. HBV DNA testing was not performed for all HBV patients; thus, we could not determine HBV reactivation as an outcome. Figure 1 . Timeline of the study periods. Chemotherapy initiation occurred from 2 months before the first chemotherapy administration until the administration of the second cycle of chemotherapy. Postchemotherapy initiation occurred after the administration of the second cycle of chemotherapy until the end of the study period (2011). Early HBV identification was defined as positive findings on HBsAg or anti-HBc tests performed before or during the chemotherapy initiation period or anti-HBV therapy before first chemotherapy. Late HBV identification was defined as positive findings on HBsAg or anti-HBc tests performed after the chemotherapy initiation period. Early anti-HBV therapy initiation was defined as HBV medication started before or during the chemotherapy initiation period and before any adverse liver outcome. Late anti-HBV therapy initiation was defined as HBV medication started after chemotherapy initiation and before or after any adverse liver outcome. Outcomes occurred from the administration of the second cycle of chemotherapy up to 2 years after the last chemotherapy administration at The University of Texas MD Anderson Cancer Center, the last follow-up, or death. Anti-HBc indicates hepatitis B core antibody; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus.
We used descriptive statistics and chi-square tests to analyze characteristics of the study cohort. Time-to-event analysis was used to compare liver-related outcomes among patients by HBV status and by the timing of HBV testing or anti-HBV therapy. Patients without outcomes were censored at the last follow-up date, the date of death, or 2 years after the last chemotherapy administration, whichever came first. Those who experienced outcomes more than 2 years after the last chemotherapy administration were censored at 2 years. Competing risk analysis for the hazard of outcomes was performed to account for competing risks of death for those who died without liver outcomes. To compare the likelihood of liver outcomes between groups, we estimated the cumulative incidence function and hazard ratios (HRs) for the liver failure subdistribution with the Fine-Gray model. 13 Multivariate subdistribution hazard models were developed to separately determine predictors of liver failure among HBV patients with solid tumors or hematologic malignancies. Covariates included demographics, the HBV status, and the timing of HBV identification and anti-HBV therapy. Rituximab administration and stem cell transplantation, treated as time-varying covariates, were also included for patients with hematologic malignancies. The model selection implemented stepwise methods by which the P value for entry was .10 and the P value to remain was .05. Because of the strong correlation between the timing of HBV identification and the timing of the initiation of anti-HBV therapy, we explored multivariate models in which either one of the two was excluded.
RESULTS
A total of 18,688 patients received chemotherapy during the study period, and 80.4% (n 5 15,031) had solid tumors, whereas 19.6% (n 5 3657) had hematologic malignancies (Table 1) . Overall, 19.9% had early HBV testing, 6.3% had late testing, and 73.8% were not tested. Among the 4905 tested patients, the overall prevalence of chronic HBV infection was 1.1% (n 5 52), and the overall prevalence of past HBV infection was 7.1% (n 5 350). The prevalence among patients with hematologic malignancies was 0.8% for chronic HBV (25 of 3277) and 6.0% (196 of 3277) for past HBV. The prevalence among patients with solid tumors was 1.7% (27 of 1628) for chronic HBV and 9.5% (154 of 1628) for past HBV. Among Asian and black patients with solid tumors, the prevalence was 11.8% and 2.1% for chronic infection and 34.2% and 12.2% for past infection, respectively. Twenty-six of 52 chronic HBV patients had serum HBV DNA testing (median, 16 days after HBV identification; range, 2 days to 7 months); 12 had undetectable HBV DNA, and 14 had detectable HBV DNA (median, 49,350 IU/mL; range, 1930-50,000,000 IU/mL).
The median follow-up duration for the study cohort was 26 months (range, 2 days to 88.6 months). The incidence of each liver outcome was higher for chronic or past HBV patients versus HBV-negative patients and for patients with late HBV identification versus those with early HBV identification and was lowest for the untested patients ( Table 2 ). The incidence of liver failure for patients with solid or hematologic tumors was 11.7% when the HBV infection was diagnosed late, 7.4% when the HBV infection was diagnosed early, and 7.8% without an HBV infection ( Table 2) . Of the patients with a chronic or past HBV infection and liver failure, 53% (n 5 18) developed liver failure while receiving chemotherapy, and 47% (n 5 16) developed liver failure after the last chemotherapy cycle.
Among patients with solid tumors, late identification of chronic HBV was significantly associated with a higher risk of hepatitis flare (hazard ratio (Table 3) . Among the 181 patients with solid tumors and chronic or past HBV infections, 15 patients had liver failure. Of these, 6 had colorectal cancer, 3 had other gastrointestinal cancers (esophageal cancer [n 5 1], stomach cancer [n 5 1], and pancreatic cancer [n 5 1]), 2 had breast cancer, 2 had lung cancer, 1 had melanoma, and 1 had thymoma. Figure 2 shows a significantly higher cumulative incidence of liver failure for solid tumor patients with late identification of chronic HBV versus early identification. For patients with hematologic malignancies, we could not fully evaluate the effect of the timing of chronic HBV identification on liver impairment or liver failure because of the small numbers of patients with late identification. Early identification was defined as positive findings on HBsAg or anti-HBc tests performed before or during the chemotherapy initiation period or anti-HBV therapy before first chemotherapy. Late identification was defined as HBsAg or anti-HBc tests performed after the chemotherapy initiation period.
c Early initiation occurred during the chemotherapy initiation period before any adverse liver outcome. Late initiation occurred after the chemotherapy initiation period before or after an adverse liver outcome.
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There was no significant association between the timing of anti-HBV therapy and liver failure (Table 4) . However, we found that the timing of HBV identification and the timing of anti-HBV therapy were highly correlated: among the 39 chronic HBV patients who had early testing, 23 started anti-HBV therapy before or at the initiation of cancer therapy, whereas all 13 chronic HBV patients who had late identification had late/no anti-HBV therapy. Among patients with hematologic malignancies, the risk of a hepatitis flare (HR, 3.13; 95% CI, 1.24-7.92) or hepatic impairment (HR, 5.09; 95% CI, 1.19-21.74) for past HBV patients and the risk of death for chronic HBV patients (HR, 7.82; 95% CI, 1.73-35.27) were significantly higher for persons with late anti-HBV therapy initiation in comparison with those with early anti-HBV therapy initiation (Table 4) . Among patients who received rituximab, all 12 with chronic HBV and 31 of 103 with past HBV had early initiation of anti-HBV therapy. For patients with solid tumors, we could not fully evaluate the effect of the timing of anti-HBV therapy on liver failure because of the small numbers of patients.
Among patients with solid tumors, those with chronic HBV had a higher risk of liver failure than those with past HBV (HR, 4.94; 95% CI, 1.82-13.45), and those with late identification of an HBV infection had a higher risk of liver failure than those with early identification (HR, 2.86; 95% CI, 0.99-8.24; Table 5 ). Male sex was also a predictor of liver failure among solid tumor patients. For patients with hematologic malignancies, chronic HBV was a predictor of liver failure (HR, 3.34; 95% CI, 1.10-10.17; Table 5 ).
DISCUSSION
In this analysis of a large cohort of patients receiving anticancer therapy, we found that late identification of chronic HBV after chemotherapy initiation for solid tumors led to higher risks of adverse liver outcomes in comparison with early HBV detection. We also found that late or no anti-HBV therapy was associated with higher rates of mortality than early anti-HBV therapy for chronic HBV patients with hematologic malignancies. The timing of the identification of an HBV infection was correlated with the timing of anti-HBV therapy, and this suggests that the benefits of early HBV identification could be related to the early use of anti-HBV therapy or to close monitoring and early anti-HBV treatment at the first sign of a hepatitis flare.
Among the more than 15,000 patients in our study who had solid tumors, a chronic HBV infection and the late identification of a chronic or past HBV infection were independent risk factors for liver failure. The late identification of a chronic HBV infection was also associated with higher rates of hepatitis flare, hepatic impairment, and all-cause mortality. Previous studies have not examined the impact of early testing versus late testing on adverse liver outcomes in patients with solid tumors. In one study in which breast, colon, or lung cancer patients were screened before chemotherapy, there were no cases of liver failure among 30 patients with a chronic HBV infection with early HBV testing, of whom 28 had undergone early anti-HBV therapy.
14 In contrast, the rate of liver failure in our study was 6.7% for solid tumor patients with chronic HBV, and it was likely higher because none had early anti-HBV therapy.
Among patients with hematologic malignancies who had HBV testing, more than 90% were tested early. Because of the low numbers for late testing, we did not observe any difference in outcomes between patients with early HBV infection identification and patients with late identification. However, we found a 7.82 (95% CI, 1.73-35.27) times higher risk of death for chronic HBV patients with late/no anti-HBV therapy in comparison with those with early therapy. Data from randomized clinical trials have supported the benefit of early anti-HBV therapy among patients with hematologic malignancies. In one study of 30 lymphoma patients with chronic HBV, 0 of 15 patients in the prophylaxis group and 1 of 15 in the group that was closely monitored with anti-HBV medication initiated upon an HBV DNA elevation died. 15 In our study, the mortality rate was higher, 3 of 17 in the early anti-HBV therapy group and 6 of 8 in the late/no anti-HBV therapy group, likely because of less Original Article 
